Use of peptidic vasopression receptor agonists

Use of a compound having the formula (I]

• wherein:
• R1 is selected from H and part of an alicyclic structure that comprises from 3 to 8 carbon atoms;
• R2 is selected from (CH2)m—X and part of said alicyclic structure;
• m is selected from 0, 1, 2 and 3;
• n is selected from 0, 1, 2, 3 and 4;
• p is selected from 2, 3 and 4;
• when R1 is H, R2 is (CH2)m—X;
• when R1 is not H, R1 and R2 together with the α carbon atom to which they are attached form said alicyclic structure;
• when m is 0, 2 or 3, X is selected from C3-8-cycloalkyl, C5-8-cycloalkenyl and C5-8-cycloalkynyl;
• when m is 1, X is selected from C3-8-cycloalkyl, C5-8-cycloalkenyl, C5-8-cycloalkynyl, isopropyl and tert-butyl;
• said alicyclic structure, C3-8-cycloalkyl, C5-8-cyclo-alkenyl and
• C5-8-cycloalkynyl optionally have at least one alkyl, O-alkyl or hydroxyl substituent;
• R3, R4, R5, R6, R7 and R8 are each independently selected from H, alkyl, OH, O-alkyl and OC(O)-alkyl;
• alkyl is selected from C1-6 straight and C4-8 branched chain alkyl and optionally has at least one hydroxyl substituent;
• and
• solvates and pharmaceutically acceptable salts thereof;
• for the manufacture of a medicament for treatment of hypertensive gastropathy bleeding, sepsis, severe sepsis, septic shock, prolonged and severe hypotension, intradialytic hypotension, cardiac arrest, trauma related blood loss, vasodilatory shock induced by cardiopulmonary bypass, milrinone-induced vasodilatory shock in congestive heart failure, hepatorenal syndrome type I, anaphylactic shock, or cardiovascular instability induced by brain death.